A comprehensive new review led by Mayo Clinic focuses on the latest advances in personalized patient-centered care and precision oncology to help shape the way clinicians diagnose and treat meningiomas, the most common primary brain tumor.
This review, published in Nature Reviews Clinical Oncology, brings together global expertise to chart the future of meningioma treatment, highlighting innovations aimed at improving patient outcomes and quality of life.
“This study synthesizes rapidly evolving science to support more individualized care for meningioma patients,” said Ghelareh Zadeh, MD, chief of neurosurgery at the Mayo Clinic in Rochester and senior author of the review. “With insights and technologies emerging rapidly, there is an urgent need to translate new knowledge into clinical practice. This review will help healthcare teams make more informed decisions and improve patient outcomes and quality of life.”
Putting the patient first through precision medicine
Meningiomas account for approximately 37% of all central nervous system tumors and, depending on their location, can have a significant impact on neurological function.
Traditionally, treatment decisions relied on the appearance of the tumor under the microscope. This review highlights the major shift in integrating molecular, imaging, and clinical data to personalize care for each patient. Key advances include:
- More accurate diagnosis and prognosis. New molecular classification systems improve the ability to predict which tumors are likely to grow or relapse, allowing for earlier and more personalized treatment decisions.
- Early detection of recurrence. Advanced imaging such as PET/MRI allows clinicians to detect residual or recurrent tumors earlier and guide timely treatment.
- Less invasive and safer treatment. Innovations in surgical techniques and precision radiation therapy improve outcomes while reducing complications and preserving function.
A more personalized treatment pathway
This review outlines the latest multidisciplinary approaches to meningioma care, approaches that are tailored to each patient rather than relying on a generalized approach. For some patients, that may mean active monitoring to avoid unnecessary treatments and maintain quality of life. Advances in minimally invasive surgery and highly targeted radiation therapy are making treatment safer and more precise for some people.
At the same time, new options are emerging for more complex cases. Targeted drugs, immunotherapies, and radioligand therapies are expanding what is possible for patients with aggressive or recurrent tumors. These treatments are increasingly guided by molecular profiling and advanced imaging, helping treatment teams better understand each tumor and choose the most effective approach.
These advances will allow the treatment of meningioma to move toward more individualized and timely treatment, improving outcomes while reducing unnecessary interventions.
“This is redefining how patients with the most common type of brain tumor are cared for,” Dr. Zadeh says. “This allows us to move beyond a one-size-fits-all approach and toward more personalized care.”
sauce:
Reference magazines:
Assadi, M., Juweid, ME, Lohmann, P., Minniti, G., Sahm, F., Ivanidze, J., Karschnia, P., Landry, A., Mottaghy, F. M., and Zadeh, G. (2026). Multidisciplinary management of meningioma in the era of precision oncology. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-026-01148-9. https://www.nature.com/articles/s41571-026-01148-9
